(Approval lapsed) Vinorelbine Injection USP 50mg/5mL vial (Sagent)
Section 19A approved medicine
(Approval lapsed) Vinorelbine Injection USP 50mg/5mL vial (Sagent)
Section 19A approval holder
Link Medical Products Pty Ltd ABN 73 010 971 517
Phone
1800 181 060
Approved until
Status
Expired
Medicines in short supply/unavailable
NAVELBINE vinorelbine 50mg/5mL (as tartrate) injection vial - AUST R: 62248
Indication(s)
NAVELBINE is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.
NAVELBINE is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage IB or greater.